Sobi - Swedish Orphan Biovitrum AB (publ) in the news

Swedish Orphan Biovitrum AB (publ) is a biopharma company providing medicines in haematology, immunology, and specialty care with a global presence and various partnerships.

Sobi is a biopharmaceutical company focused on developing and commercializing therapies in haematology, immunology, and specialty care globally.

Sobi paid Innate Pharma $75 million as their strategic partnership became effective, granting Sobi exclusive global commercialization rights for lacutamab.

Sobi and Innate Pharma's strategic partnership is now effective, enabling the initiation of a Phase 3 study for lacutamab and granting Sobi global commercialisation rights.

Sobi's pacritinib received US FDA Fast Track designation for VEXAS syndrome, accelerating its development for this debilitating condition.

Sobi completed an issue of class C shares to Svenska Handelsbanken AB to secure its employee incentive program.

Sobi completed an issue of class C shares to Svenska Handelsbanken AB to secure its employee incentive program obligations, with plans to repurchase and convert them into common shares.

Sobi completed an issue of class C shares to Svenska Handelsbanken AB to fund an employee incentive program, with plans to repurchase and convert them into common shares.

Sobi completed a directed issue of class C shares to Svenska Handelsbanken AB to support its employee incentive program.

Innate Pharma and Sobi have partnered to advance lacutamab, a T-cell lymphoma therapy, through a Phase 3 study, with Sobi securing global commercialization rights.

Sobi has partnered with Innate Pharma to license lacutamab, initiating a Phase 3 study for T-cell lymphoma with an upfront payment of $75 million and potential milestones.

Innate Pharma partnered with Sobi to advance lacutamab for cutaneous T-cell lymphoma, initiating a Phase 3 trial and granting Sobi global commercial rights.

Innate Pharma and Sobi formed a partnership for the clinical development and commercialization of lacutamab, a rare T-cell lymphoma therapy.

Sobi's Board authorized the repurchase of Class C shares to fulfill obligations under an employee incentive program, with these shares later converting to common shares.

Sobi partnered with Innate Pharma to license lacutamab for T-cell lymphoma, planning a Phase 3 study for accelerated approval in Sézary syndrome, with Sobi gaining exclusive global commercial rights and Innate receiving upfront and milestone payments plus royalties.

Swedish Orphan Biovitrum AB has seen significant insider selling, particularly from its CEO, raising concerns despite a reasonable level of insider ownership.

Sobi and Innate Pharma formed a partnership for lacutamab, a T-cell lymphoma treatment, with Sobi gaining commercial rights and Innate receiving upfront and milestone payments.

Swedish Orphan Biovitrum AB has seen significant insider selling, particularly by its CEO, outweighing insider buying over the past year.

Guido Oelkers is resigning as CEO of Sobi by early 2027 after nearly a decade, with the company initiating a search for a successor.

Guido Oelkers is stepping down as CEO of Sobi by early 2027, prompting the board to seek a successor while the company's strategy and financial goals remain unchanged.